Understanding Your Diagnosis: Biology & Subtypes
Last updated:
Myotonic dystrophy is a genetic condition causing progressive muscle weakness and difficulty relaxing muscles (myotonia). Type 1 (DM1) is typically more severe and affects distal muscles, while Type 2 (DM2) affects proximal muscles. Both are caused by DNA repeat expansions that create toxic RNA.
Key Takeaways
- • Myotonic dystrophy involves myotonia (difficulty relaxing muscles) and progressive muscle weakness.
- • Type 1 (DM1) affects hands, feet, and face first, while Type 2 (DM2) affects hips, shoulders, and thighs.
- • DM1 features genetic anticipation, meaning the disease can become more severe in future generations.
- • The condition is driven by a genetic glitch that creates toxic RNA, which disrupts normal cellular function.
- • Because it is an inherited condition, consulting a genetic counselor is critical for family planning.
Receiving a diagnosis of Myotonic Dystrophy can feel overwhelming, but understanding the biology of the condition is a powerful first step toward managing it. At its core, Myotonic Dystrophy is a genetic condition that affects how your muscles work and how your body processes information from your DNA [1].
The name itself describes the two main features: myotonia (difficulty relaxing muscles after a contraction, like a “sticky” grip) and dystrophy (progressive muscle wasting or weakness over time) [2].
The Two Main Types: DM1 and DM2
While they share a name, Myotonic Dystrophy Type 1 (DM1) and Type 2 (DM2) are caused by different genetic “glitches” on different chromosomes [1].
| Feature | Myotonic Dystrophy Type 1 (DM1) | Myotonic Dystrophy Type 2 (DM2) |
|---|---|---|
| Genetic Cause | CTG repeat on the DMPK gene (Chromosome 19) [1] | CCTG repeat on the CNBP gene (Chromosome 3) [1] |
| Muscle Focus | Distal: Affects hands, feet, and face first [3] | Proximal: Affects hips, shoulders, and thighs first [3] |
| Severity | Ranges from mild to severe (congenital) [4] | Generally milder; no congenital form [5] |
| Prevalence | Approximately 1 in 8,000 people [6] | Much rarer; often five times less common than DM1 [7] |
Myotonic Dystrophy Type 1 (DM1)
DM1 is the more common form. It is characterized by a “repeat expansion,” where a small segment of DNA (CTG) repeats many more times than it should [1].
- Genetic Anticipation: This is a unique feature of DM1 where the condition may appear earlier and with more severe symptoms in each successive generation [8]. This happens because the DNA repeat often grows longer as it is passed from parent to child [9].
- Congenital Form: DM1 has a severe “congenital” form that is present at birth, typically occurring when a child inherits a very large number of repeats (often over 1,000) [4].
Myotonic Dystrophy Type 2 (DM2)
DM2 is sometimes called PROMM (Proximal Myotonic Myopathy) [10].
- Milder Progression: DM2 generally starts in adulthood and typically does not have the severe breathing or feeding issues seen in infants with DM1 [5].
- No Clear Anticipation: Unlike DM1, the symptoms of DM2 do not consistently get worse or start earlier in future generations [8].
The Biological Mechanism: “Toxic RNA”
You might hear doctors talk about a toxic RNA gain-of-function. To understand this, think of your DNA as a library of instruction manuals.
- The Glitch: The expanded repeats in your DNA create long, “sticky” strands of RNA (the messenger that carries instructions) [1].
- The Sponge: This “toxic” RNA acts like a sponge, soaking up important proteins in the cell, specifically one called MBNL [11].
- The Spliceopathy: Because the MBNL protein is stuck to the toxic RNA, it cannot do its normal job of helping the cell “edit” other genetic instructions [1]. This leads to a spliceopathy—a state where many different proteins in your body (including those for muscle relaxation and heart rhythm) are built incorrectly because the instructions were not edited right [11][12].
Managing Symptoms: Myotonia
The “stickiness” in your muscles is caused by a shortage of working chloride channels in the muscle cells [12].
- Mexiletine: This is a medication often used to help muscles relax more easily [13].
- Cardiac Caution: Because Myotonic Dystrophy can also affect the electrical system of the heart, doctors must perform an EKG (heart rhythm test) before starting medications like mexiletine to ensure they are safe for your specific heart profile [14].
Genetic Counseling & Family Planning
Because Myotonic Dystrophy is an inherited genetic condition, your diagnosis has direct implications for your family [8]. In DM1, genetic anticipation means the condition can appear earlier and more severely in your children [9]. It is critical to consult a genetic counselor to discuss family planning options and whether your children, siblings, or parents should be tested [4].
Frequently Asked Questions
What is the difference between myotonic dystrophy type 1 and type 2?
What does genetic anticipation mean in myotonic dystrophy?
Why do my hands get stuck or have trouble relaxing after gripping something?
Is there a treatment for the muscle stiffness in myotonic dystrophy?
Should my family members be tested if I am diagnosed with myotonic dystrophy?
Questions for Your Doctor
- • Based on my genetic test, do I have Myotonic Dystrophy Type 1 (DM1) or Type 2 (DM2)?
- • What was the exact number of repeats found in my genetic test, and what does that typically mean for the progression of my symptoms?
- • Since DM1 can show 'genetic anticipation,' what should I know about the risks for my children or future children?
- • Can you refer me to a genetic counselor to discuss testing options for my extended family?
Questions for You
- • Which muscle groups do I notice are most affected—is it my hands and feet (distal) or my hips and shoulders (proximal)?
- • When I grip an object tightly, like a doorknob or a tool, do my hands 'stick' or take several seconds to relax?
- • Are there other family members who have had similar muscle issues, cataracts at a young age, or unexplained heart problems?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.
LoRusso S, Weiner B, Arnold WD
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2018; (15(4)):872-884 doi:10.1007/s13311-018-00679-z.
PMID: 30341596 - 2
A Case of Myotonic Dystrophy Type I With Rimmed Vacuoles in Skeletal Muscle Pathology.
Ban R, Zhang Y, Li K, Shi Q
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2021; (27(8S)):S771-S772 doi:10.1097/RHU.0000000000001496.
PMID: 32732524 - 3
Myotonic dystrophy type 2: the 2020 update.
Meola G
Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2020; (39(4)):222-234 doi:10.36185/2532-1900-026.
PMID: 33458578 - 4
Clinical and genetic characteristics of childhood-onset myotonic dystrophy.
Stokes M, Varughese N, Iannaccone S, Castro D
Muscle & nerve 2019; (60(6)):732-738 doi:10.1002/mus.26716.
PMID: 31520483 - 5
Generation of a lymphoblastoid-derived induced pluripotent stem cell line (CBRCULi015-A) from a patient with congenital myotonic dystrophy.
De Serres-Bérard T, Jauvin D, Pouliot V, et al.
Stem cell research 2024; (77()):103430 doi:10.1016/j.scr.2024.103430.
PMID: 38704930 - 6
Myotonic dystrophy type 1 drug development: A pipeline toward the market.
Pascual-Gilabert M, López-Castel A, Artero R
Drug discovery today 2021; (26(7)):1765-1772 doi:10.1016/j.drudis.2021.03.024.
PMID: 33798646 - 7
Myotonic Muscular Dystrophy Type 2 in CT, USA: A Single-Center Experience With 50 Patients.
Roy B, Wu Q, Whitaker CH, Felice KJ
Journal of clinical neuromuscular disease 2021; (22(3)):135-146 doi:10.1097/CND.0000000000000340.
PMID: 33595997 - 8
Unusual association of a unique CAG interruption in 5' of DM1 CTG repeats with intergenerational contractions and low somatic mosaicism.
Tomé S, Dandelot E, Dogan C, et al.
Human mutation 2018; (39(7)):970-982 doi:10.1002/humu.23531.
PMID: 29664219 - 9
DM1 Phenotype Variability and Triplet Repeat Instability: Challenges in the Development of New Therapies.
Tomé S, Gourdon G
International journal of molecular sciences 2020; (21(2)) doi:10.3390/ijms21020457.
PMID: 31936870 - 10
Sporadic Myotonic Dystrophy Type 2 in a Japanese Patient.
Miyashita K, Ii Y, Matsuyama H, et al.
Internal medicine (Tokyo, Japan) 2023; (62(20)):3027-3031 doi:10.2169/internalmedicine.0425-22.
PMID: 36792202 - 11
Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model.
Neault N, Ravel-Chapuis A, Baird SD, et al.
International journal of molecular sciences 2023; (24(4)) doi:10.3390/ijms24043794.
PMID: 36835205 - 12
Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
Yadava RS, Yu Q, Mandal M, et al.
Human molecular genetics 2020; (29(9)):1440-1453 doi:10.1093/hmg/ddaa060.
PMID: 32242217 - 13
Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia.
Locci S, Cardani R, Brunori P, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(12)):5365-5368 doi:10.1007/s10072-021-05538-y.
PMID: 34386887 - 14
Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy.
Wahbi K, Bassez G, Duchateau J, et al.
Archives of cardiovascular diseases 2024; (117(6-7)):450-456 doi:10.1016/j.acvd.2024.03.001.
PMID: 38677940
This page explains the biology and genetic subtypes of myotonic dystrophy for educational purposes. Always consult a genetic counselor or neurologist for personalized medical advice, testing, and family planning.
Stay up to date
Get notified when new research about Myotonic dystrophy is published.
No spam. Unsubscribe anytime.